Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesCell Therapeutics Applies for European Orphan Drug Designation for Pixantrone in Aggressive Non-Hodgkins Lymphoma
Cell Therapeutics, 10/07/09
Cell Therapeutics, Inc. announced that it has applied to the European Medicines Agency for orphan drug designation for pixantrone. CTI initiated the process of obtaining marketing approval in Europe in July, 2009, for the treatment of relapsed or refractory aggressive NHL. CTI anticipates the formal Marketing Authorization Application filing in 2010 following approval of the pediatric investigation plan which was submitted to the EMEA earlier this month. CTI would be granted 10 year market exclusivity in Europe if the MAA is approved.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Telmisartan/amlodipine: approved for high blood pressure
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor